open access

Vol 72, No 5 (2021)
Original paper
Submitted: 2021-02-10
Accepted: 2021-05-06
Early publication date: 2021-05-31
Get Citation

Serum zonulin levels in type 2 diabetes patients with diabetic kidney disease

Fevziye Burcu Sirin1, Hakan Korkmaz2, Ismet Eroglu3, Barıs Afsar4, Duygu Kumbul Doguc1
DOI: 10.5603/EP.a2021.0056
·
Pubmed: 34057189
·
Endokrynol Pol 2021;72(5):545-549.
Affiliations
  1. Department of Medical Biochemistry, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey
  2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey
  3. Department of Internal Medicine, Isparta State Hospital, Isparta, Turkey
  4. Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey

open access

Vol 72, No 5 (2021)
Original Paper
Submitted: 2021-02-10
Accepted: 2021-05-06
Early publication date: 2021-05-31

Abstract

Introduction: Recent data have shown that diabetic kidney disease (DKD) is associated with abnormal gut microbiota composition. Zonulin is a physiological tight junction modulator and an intestinal permeability marker. In this study we aimed to investigate serum levels of zonulin and interleukin 6 (IL-6) in patients with type 2 diabetes mellitus (T2DM) and different levels of albuminuria.

Material and methods: Ninety patients with T2DM and 30 healthy controls (HC) aged between 18 and 65 years were enrolled in the study. T2DM patients were divided into three groups as patients with normoalbuminuria (n = 30), microalbuminuria (n = 30), and macroalbuminuria (n = 30). Serum zonulin and IL-6 levels were measured by ELISA method.

Results: There was no significant difference between groups in terms of age, gender, serum ALT, LDL-C, HDL-C, and zonulin levels (p > 0.05). Significant differences between groups were present for the duration of diabetes (p < 0.001), body mass index (p < 0.001), fasting blood glucose (p < 0.001), creatinine (p < 0.001), uric acid (p = 0.037), triglyceride (p = 0.003), total cholesterol (p < 0.001), glycated haemoglobin (p < 0.001), and IL-6 (p < 0.001) levels. IL-6 levels were significantly increased in the microalbuminuria and macroalbuminuria groups compared to the HC group, but no significant difference was determined between the HC and normoalbuminuria group. In patients with diabetic kidney disease, a significant positive correlation was found between zonulin with IL-6 and proteinuria (rho = 0.296, p = 0.008; rho = 0.190, p < 0.047, respectively). The serum IL-6 level was positively correlated with microalbuminuria and proteinuria (rho = 0.451, p < 0.001; rho = 0.425, p < 0.001, respectively). 

Conclusions: We suggest that the serum zonulin level is not a promising biomarker to assess the severity of DKD in patients with long-standing T2DM.

Abstract

Introduction: Recent data have shown that diabetic kidney disease (DKD) is associated with abnormal gut microbiota composition. Zonulin is a physiological tight junction modulator and an intestinal permeability marker. In this study we aimed to investigate serum levels of zonulin and interleukin 6 (IL-6) in patients with type 2 diabetes mellitus (T2DM) and different levels of albuminuria.

Material and methods: Ninety patients with T2DM and 30 healthy controls (HC) aged between 18 and 65 years were enrolled in the study. T2DM patients were divided into three groups as patients with normoalbuminuria (n = 30), microalbuminuria (n = 30), and macroalbuminuria (n = 30). Serum zonulin and IL-6 levels were measured by ELISA method.

Results: There was no significant difference between groups in terms of age, gender, serum ALT, LDL-C, HDL-C, and zonulin levels (p > 0.05). Significant differences between groups were present for the duration of diabetes (p < 0.001), body mass index (p < 0.001), fasting blood glucose (p < 0.001), creatinine (p < 0.001), uric acid (p = 0.037), triglyceride (p = 0.003), total cholesterol (p < 0.001), glycated haemoglobin (p < 0.001), and IL-6 (p < 0.001) levels. IL-6 levels were significantly increased in the microalbuminuria and macroalbuminuria groups compared to the HC group, but no significant difference was determined between the HC and normoalbuminuria group. In patients with diabetic kidney disease, a significant positive correlation was found between zonulin with IL-6 and proteinuria (rho = 0.296, p = 0.008; rho = 0.190, p < 0.047, respectively). The serum IL-6 level was positively correlated with microalbuminuria and proteinuria (rho = 0.451, p < 0.001; rho = 0.425, p < 0.001, respectively). 

Conclusions: We suggest that the serum zonulin level is not a promising biomarker to assess the severity of DKD in patients with long-standing T2DM.

Get Citation

Keywords

type 2 diabetes mellitus; diabetic kidney disease; intestinal permeability; zonulin; inflammation

About this article
Title

Serum zonulin levels in type 2 diabetes patients with diabetic kidney disease

Journal

Endokrynologia Polska

Issue

Vol 72, No 5 (2021)

Article type

Original paper

Pages

545-549

Early publication date

2021-05-31

Page views

2783

Article views/downloads

305

DOI

10.5603/EP.a2021.0056

Pubmed

34057189

Bibliographic record

Endokrynol Pol 2021;72(5):545-549.

Keywords

type 2 diabetes mellitus
diabetic kidney disease
intestinal permeability
zonulin
inflammation

Authors

Fevziye Burcu Sirin
Hakan Korkmaz
Ismet Eroglu
Barıs Afsar
Duygu Kumbul Doguc

References (22)
  1. Rabkin R. Diabetic nephropathy. Clinical Cornerstone. 2003; 5(2): 1–11.
  2. Fernandes R, Viana SD, Nunes S, et al. Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(7): 1876–1897.
  3. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013; 124(3): 139–152.
  4. Wing MR, Patel SS, Ramezani A, et al. Gut microbiome in chronic kidney disease. Exp Physiol. 2016; 101(4): 471–477.
  5. Khoury T, Tzukert K, Abel R, et al. The gut-kidney axis in chronic renal failure: A new potential target for therapy. Hemodial Int. 2017; 21(3): 323–334.
  6. Kanbay M, Onal EM, Afsar B, et al. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. Int Urol Nephrol. 2018; 50(8): 1453–1466.
  7. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000; 355(9214): 1518–1519.
  8. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011; 91(1): 151–175.
  9. Brock M, Trenkmann M, Gay RE, et al. MicroRNA-18a enhances the interleukin-6-mediated production of the acute-phase proteins fibrinogen and haptoglobin in human hepatocytes. J Biol Chem. 2011; 286(46): 40142–40150.
  10. Moreno-Navarrete JM, Sabater M, Ortega F, et al. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One. 2012; 7(5): e37160.
  11. Sapone A, de Magistris L, Pietzak M, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006; 55(5): 1443–1449.
  12. Zhang D, Zhang L, Zheng Y, et al. Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin Pract. 2014; 106(2): 312–318.
  13. Jayashree B, Bibin YS, Prabhu D, et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014; 388(1-2): 203–210.
  14. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  15. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604–612.
  16. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005; 308(5728): 1635–1638.
  17. Ahmadi S, Razazan A, Nagpal R, et al. Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. J Gerontol A Biol Sci Med Sci. 2020; 75(7): e9–ee21.
  18. Winther SA, Henriksen P, Vogt JK, et al. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. Diabetologia. 2020; 63(12): 2713–2724.
  19. Kikuchi K, Saigusa D, Kanemitsu Y, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019; 10(1): 1835.
  20. Al-Obaide MAI, Singh R, Datta P, et al. Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD. J Clin Med. 2017; 6(9): 86.
  21. Hasslacher C, Kulozik F, Platten I. Serum zonulin as a parameter of intestinal permeability in longstanding type 2 diabetes: correlations with metabolism parameter and renal function. J Diabetes Metab Disord Control. 2018; 5(2): 58–62.
  22. Dschietzig TB, Boschann F, Ruppert J, et al. Plasma Zonulin and its Association with Kidney Function, Severity of Heart Failure, and Metabolic Inflammation. Clin Lab. 2016; 62(12): 2443–2447.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl